NOLVAMED 20 - Deus Medical

Tamoxifen's development began in 1962, with its most significant application in breast cancer treatment realized a decade later. By 1977, the FDA approved its use in combating hormone receptor-positive breast cancer. TTamoxifen functions, by attaching to estrogen receptors, in the breast tissue to stop estrogen from promoting the growth of cancer cells. Its ability to act as both an agonist and antagonist has made it widely used, not only in cancer therapy but among athletes to address the estrogen related effects brought on by anabolic steroids. 

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about NOLVAMED 20 by Deus Medical, consult with your doctor or healthcare professional.